FIELMANN AG (ADR/1/5)O.N.
Fielmann Group AG engages in vision care and audiology business in Germany, Switzerland, Austria, Spain, North America, and internationally. The company manufactures and sells visual aids mainly glasses, eyewear frames and lenses, sunglasses, contact lenses, accessories, hearing systems and its accessories, as well as personal protective equipment. It offers its products under the fielmann, Optik… Read more
FIELMANN AG (ADR/1/5)O.N. (FIE1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, FIELMANN AG (ADR/1/5)O.N. (FIE1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
FIELMANN AG (ADR/1/5)O.N. - Net Assets Trend (None–None)
This chart illustrates how FIELMANN AG (ADR/1/5)O.N.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for FIELMANN AG (ADR/1/5)O.N. (None–None)
The table below shows the annual net assets of FIELMANN AG (ADR/1/5)O.N. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to FIELMANN AG (ADR/1/5)O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
FIELMANN AG (ADR/1/5)O.N. Competitors by Market Cap
The table below lists competitors of FIELMANN AG (ADR/1/5)O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Launch Two Acquisition Corp. Class A Ordinary Shares
NASDAQ:LPBB
|
$188.65 Million |
|
Padini Holdings Bhd
KLSE:7052
|
$188.83 Million |
|
Oisix ra daichi Inc
OTCGREY:OISXF
|
$188.87 Million |
|
Lionheart Holdings Unit
NASDAQ:CUBWU
|
$188.88 Million |
|
SOUTHERN STS BANCSH. DL 5
F:6U2
|
$188.59 Million |
|
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
|
$188.58 Million |
|
Sichuan Dowell Science and Technology Inc
SHE:300535
|
$188.52 Million |
|
Nanjing Res In of Surveying Mapping
SHE:300826
|
$188.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in FIELMANN AG (ADR/1/5)O.N.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares FIELMANN AG (ADR/1/5)O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently FIELMANN AG (ADR/1/5)O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares FIELMANN AG (ADR/1/5)O.N.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $9,394,036,854
- Average return on equity (ROE) among peers: 4.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| FIELMANN AG (ADR/1/5)O.N. (FIE1) | €- | N/A | N/A | $188.61 Million |
| Modern Dental Group Limited (1MD) | $2.36 Billion | 15.30% | 0.55x | $193.75 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $482.88 Million |
| Alcon Inc. (2U3) | $19.26 Billion | 1.95% | 0.45x | $33.73 Billion |
| Shofu Inc. (69W) | $35.51 Billion | 8.83% | 0.23x | $215.32 Million |
| 7VG (7VG) | $176.36 Million | 14.92% | 1.12x | $684.88 Million |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $2.79 Million |
| Paul Hartmann AG (PHH2) | $690.37 Million | 10.65% | 0.81x | $776.29 Million |
| Sartorius AG VZO O.N. (SRT) | $497.08 Million | 9.76% | 1.56x | $6.78 Billion |
| Shandong Weigao Group Medical Polymer Company Limited (UK2) | $25.34 Billion | 8.16% | 0.37x | $1.36 Billion |